Sientra Inc (SIEN.OQ)
12.99USD
25 Apr 2018
$-0.79 (-5.73%)
$13.78
$13.80
$13.97
$12.76
168,094
87,434
$16.61
$7.21
About
Overall
Beta: | -- |
Market Cap(Mil.): | $307.56 |
Shares Outstanding(Mil.): | 19.31 |
Dividend: | -- |
Yield (%): | -- |
Financials
SIEN.OQ | Industry | Sector | |
---|---|---|---|
P/E (TTM): | -- | 32.19 | 32.74 |
EPS (TTM): | -2.66 | -- | -- |
ROI: | -61.89 | 13.89 | 14.38 |
ROE: | -64.43 | 16.72 | 16.07 |
BRIEF-Sientra Sees Preliminary Unaudited Net Sales For Q1 2018 Of About $14.5 Mln
* SIENTRA INC - SEES PRELIMINARY UNAUDITED NET SALES FOR Q1 2018 OF ABOUT $14.5 MILLION
BRIEF-Sientra Receives FDA Approval Of PMA Supplement
* SIENTRA INC - ADDITIONAL $10 MILLION OF EXISTING CREDIT FACILITY NOW ACCESSIBLE WITH FDA APPROVAL
BRIEF-Sientra Says Reached An Agreement-In-Principle With Staff Of Division Of Enforcement Of U.S. SEC
* SIENTRA INC - REACHED AN AGREEMENT-IN-PRINCIPLE WITH STAFF OF DIVISION OF ENFORCEMENT OF U.S. SECURITIES AND EXCHANGE COMMISSION - SEC FILING
BRIEF-Sientra Reports Qtrly Loss Per Share $0.92
* SIENTRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
BRIEF-Sientra Says Co Enters Into Agreement With Stifel, Nicolaus & Co Inc
* SIENTRA SAYS CO ENTERED INTO AGREEMENT WITH STIFEL, NICOLAUS & CO INC, TO SELL SHARES OF STOCK HAVING AN OFFERING PRICE OF UP TO $50 MILLION- SEC FILING Source text for Eikon: Further company coverage:
BRIEF-Sientra Provides Update On FDA Review Of U.S. Manufacturing Facility
* SIENTRA® PROVIDES UPDATE ON FDA REVIEW OF U.S. MANUFACTURING FACILITY
BRIEF-Sientra Announces Preliminary Unaudited Q4 Revenue
* SIENTRA ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER 2017 REVENUE
BRIEF-Sientra Inc Files For Mixed Shelf Of Upto $150 Million
* SIENTRA INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text (http://bit.ly/2ADjKzY) Further company coverage:
BRIEF-Sientra posts qtrly loss of $0.74 per share
* Total net sales for Q3 2017 were $9.8 million, compared to total net sales of $6.5 million for same period in 2016
BRIEF-Sientra's total net sales for Q3 2017 were $9.8 million
* Sientra - total net sales for Q3 2017 were $9.8 million, compared to $6.5 million for same period in 2016
Competitors
Price | Chg | |
---|---|---|
Allergan plc (AGN.N) | $157.12 | +0.22 |
Johnson & Johnson (JNJ.N) | $126.76 | +0.57 |